trending Market Intelligence /marketintelligence/en/news-insights/trending/go5oIMGbQt0xRfjmzEK3pA2 content esgSubNav
In This List

Genmab Q2 profit up YOY


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Genmab Q2 profit up YOY

Genmab A/S more than doubled its second-quarter operating profit year over year.

Earnings excluding some items, which the company calls operating result, were 536.4 million Danish kroner, up from 141.8 million Danish kroner in the same period of 2016.

Genmab bagged 773.3 million kroner in revenues, up from 353.8 million kroner a year earlier. Genmab's results were mainly driven by the royalties and milestone payments from its cancer drug DARZALEX.

Genmab continues to target full-year operating income of between 900 million kroner and 1.10 billion kroner; revenue is expected to be in the range of 1.95 billion kroner to 2.15 billion kroner.

On a reported basis, second-quarter net income of 307.3 million kroner compared to 168.2 million kroner in the same period of 2016.

As of Aug. 8, US$1 was equivalent to 6.34 Danish kroner.